SCM
ASMB icon

Segantii Capital Management’s Assembly Biosciences ASMB Stock Holding History

Segantii Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,643
Closed -$502K – 77
2017
Q1 		$502K Buy
1,643
+1,393
+557% +$342K 0.08% 83
2016
Q4 		$35K Buy
+250
New +$37.2K 0.01% 87

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Segantii Capital Management's ASMB Position: Q2 2017 in Review

Segantii Capital Management sold out of Assembly Biosciences (ASMB) in Q2 2017, closing a stake of 1,643 shares — an estimated $502K sold.

Segantii Capital Management first reported a position in ASMB in Q4 2016 and held it in 2 quarters. The position peaked at $502K in Q1 2017. 65 funds tracked by Wall St. Rank hold ASMB as of Q2 2017.

  • Segantii Capital Management reported no remaining Assembly Biosciences position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,643 Assembly Biosciences shares in Q2 2017, an estimated $502K.
  • Segantii Capital Management first reported a position in Assembly Biosciences in Q4 2016 and held it in 2 quarters.
  • Segantii Capital Management's Assembly Biosciences position peaked at $502K in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.